Zentalis Pharmaceuticals (ZNTL) Stock Statistics & Valuation Metrics

Zentalis Pharmaceuticals has a market cap or net worth of $103.61M. The enterprise value is $100.33M.

Zentalis Pharmaceuticals has 71,951,935 shares outstanding. The number of shares has decreased by -2.65% in one year.

Zentalis Pharmaceuticals’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -50.69%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Zentalis Pharmaceuticals had revenue of 67.42M and earned -165.84M in profits. Earnings per share was -2.33.

In the last 12 months, operating cash flow was -9.01M and capital expenditures -41.00K, giving a free cash flow of -9.05M billion.

Zentalis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Zentalis Pharmaceuticals upcoming earnings date is Aug 7, 2025, Before Open (Confirmed).

Zentalis Pharmaceuticals as a current ratio of 7.32, with Debt / Equity ratio of 13.09%

In the past 12 months, Zentalis Pharmaceuticals has paid 177.00K in taxes.

Zentalis Pharmaceuticals EV to EBITDA ratio is -1.16, with an EV/FCF ratio of -1.29.

Zentalis Pharmaceuticals has $332.45M in cash and marketable securities with $38.65M in debt, giving a net cash position of -$293.80M billion.

Gross margin is 97.60%, with operating margin of -283.57%, and net profit margin of -245.96%.

The average price target for Zentalis Pharmaceuticals is $6.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy